Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 26, 2014 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02407302) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02407302 | withdrawnsource: Cancelled Post Marketsince May 8, 2017 | health-canada-dpd |
| Jun 5, 2014 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-EPIRUBICIN (DIN 02410400) under ATC L01DB03 EPIRUBICIN. Indications are not published in the Drug Product… | DIN02410400 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 21, 2014 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN (DIN 02410397) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database… | DIN02410397 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 2014 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-IMATINIB (DIN 02397293) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02397293 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2014 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION (DIN 02412233) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02412233 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 27, 2014 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02409275) under ATC L01DB01 DOXORUBICIN. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 17, 2014 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GIOTRIF (DIN 02415682) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see… | DIN02415682 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 2, 2013 | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as MED-EXEMESTANE (DIN 02407841) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product… | DIN02407841 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 27, 2013 | Mercaptopurine | Health Canada CA | cancer not stated in this record | Marketed in Canada as MERCAPTOPURINE TABLETS USP (DIN 02415275) under ATC L01BB02 MERCAPTOPURINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 21, 2013 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN INJECTION (DIN 02409232) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product… | DIN02409232 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2013 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE INJECTION (DIN 02412292) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 29, 2013 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-TOPOTECAN (DIN 02406446) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product Database… | DIN02406446 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 8, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-LETROZOLE (DIN 02343657) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02343657 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| May 8, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422204) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02422204 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422190) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02422190 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422182) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02422182 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422174) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02422174 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422166) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02422166 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2014 | Aflibercept | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZALTRAP (DIN 02421089) under ATC L01XX44 AFLIBERCEPT. Indications are not published in the Drug Product Database —… | DIN02421089 | withdrawnsource: Cancelled Post Marketsince Jul 13, 2020 | health-canada-dpd |
| May 8, 2014 | Aflibercept | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZALTRAP (DIN 02421070) under ATC L01XX44 AFLIBERCEPT. Indications are not published in the Drug Product Database —… | DIN02421070 | withdrawnsource: Cancelled Post Marketsince Jul 13, 2020 | health-canada-dpd |
| May 8, 2014 | Radium Ra-223 Dichloride | Health Canada CA | cancer not stated in this record | Marketed in Canada as XOFIGO (DIN 02418398) under ATC V10XX03 RADIUM (223Ra) DICHLORIDE. Indications are not published in the Drug Product… | DIN02418398 | approvedsource: Marketed | health-canada-dpd |
| May 1, 2014 | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-EXEMESTANE (DIN 02419726) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product… | DIN02419726 | withdrawnsource: Dormantsince Aug 4, 2017 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 29, 2014 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-IMATINIB (DIN 02397285) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02397285 | approvedsource: Marketed | health-canada-dpd |
| Apr 24, 2014 | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BOSULIF (DIN 02419149) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see… | DIN02419149 | approvedsource: Marketed | health-canada-dpd |
| Apr 17, 2014 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION CONCENTRATE (DIN 02423510) under ATC L01BC05 GEMCITABINE. Indications are not published in… | DIN02423510 | withdrawnsource: Cancelled Post Marketsince Aug 7, 2017 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 17, 2018 |
| health-canada-dpd |
| Mar 28, 2014 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION (DIN 02412225) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02412225 | withdrawnsource: Cancelled Post Marketsince May 17, 2018 | health-canada-dpd |
| Mar 24, 2014 | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BOSULIF (DIN 02419157) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see… | DIN02419157 | approvedsource: Marketed | health-canada-dpd |
| Mar 12, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP-METHOTREXATE (DIN 02419173) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02419173 | withdrawnsource: Cancelled Post Marketsince Nov 14, 2022 | health-canada-dpd |
| Mar 7, 2014 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN (DIN 02410419) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database —… | DIN02410419 | withdrawnsource: Cancelled Post Marketsince Jun 3, 2022 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 11, 2014 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIVA-LETROZOLE (DIN 02398656) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02398656 | approvedsource: Marketed | health-canada-dpd |
| Feb 5, 2014 | Romidepsin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ISTODAX (DIN 02414295) under ATC L01XH02 ROMIDEPSIN. Indications are not published in the Drug Product Database — see… | DIN02414295 | approvedsource: Marketed | health-canada-dpd |
| Feb 5, 2014 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN INJECTION (DIN 02390981) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product… | DIN02390981 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 17, 2014 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GIOTRIF (DIN 02415674) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see… | DIN02415674 | approvedsource: Marketed | health-canada-dpd |
| Jan 17, 2014 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GIOTRIF (DIN 02415666) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see… | DIN02415666 | approvedsource: Marketed | health-canada-dpd |
| Jan 16, 2014 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-CYTARABINE (DIN 02406772) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product… | DIN02406772 | approvedsource: Marketed | health-canada-dpd |
| Jan 16, 2014 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-CYTARABINE (DIN 02406764) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product… | DIN02406764 | withdrawnsource: Dormantsince Jul 31, 2024 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 21, 2013 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN HYDROCHLORIDE FOR INJECTION (DIN 02396378) under ATC L01CE01 TOPOTECAN. Indications are not published in… | DIN02396378 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 30, 2021 |
| health-canada-dpd |
| Oct 16, 2013 | Triptorelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRELSTAR (DIN 02412322) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database —… | DIN02412322 | approvedsource: Marketed | health-canada-dpd |
| Oct 9, 2013 | Trastuzumab Emtansine | Health Canada CA | cancer not stated in this record | Marketed in Canada as KADCYLA (DIN 02412365) under ATC L01FD03 TRASTUZUMAB EMTANSINE. Indications are not published in the Drug Product… | DIN02412365 | approvedsource: Marketed | health-canada-dpd |
| Oct 1, 2013 | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-EXEMESTANE (DIN 02408473) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product… | DIN02408473 | withdrawnsource: Cancelled Post Marketsince Jan 17, 2025 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 9, 2013 | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRISENOX (DIN 02407833) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in the Drug Product… | DIN02407833 | withdrawnsource: Cancelled Post Marketsince Dec 16, 2022 | health-canada-dpd |
| Sep 4, 2013 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE INJECTION USP (DIN 02380935) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product… | DIN02380935 | withdrawnsource: Cancelled Post Marketsince Jul 28, 2023 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 |
| health-canada-dpd |
| Aug 29, 2013 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION (DIN 02403188) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02403188 | approvedsource: Marketed | health-canada-dpd |
| Aug 28, 2013 | Trametinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEKINIST (DIN 02409658) under ATC L01EE01 TRAMETINIB. Indications are not published in the Drug Product Database —… | DIN02409658 | approvedsource: Marketed | health-canada-dpd |
| Aug 28, 2013 | Trametinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEKINIST (DIN 02409623) under ATC L01EE01 TRAMETINIB. Indications are not published in the Drug Product Database —… | DIN02409623 | approvedsource: Marketed | health-canada-dpd |
| Aug 28, 2013 | Dabrafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAFINLAR (DIN 02409615) under ATC L01EC02 DABRAFENIB. Indications are not published in the Drug Product Database —… | DIN02409615 | approvedsource: Marketed | health-canada-dpd |
| Aug 28, 2013 | Dabrafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAFINLAR (DIN 02409607) under ATC L01EC02 DABRAFENIB. Indications are not published in the Drug Product Database —… | DIN02409607 | approvedsource: Marketed | health-canada-dpd |
| Aug 19, 2013 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-CAPECITABINE (DIN 02400030) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02400030 | withdrawnsource: Cancelled Post Marketsince Mar 16, 2022 | health-canada-dpd |
| Aug 19, 2013 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-CAPECITABINE (DIN 02400022) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02400022 | withdrawnsource: Cancelled Post Marketsince Mar 16, 2022 | health-canada-dpd |
| Aug 9, 2013 | Vismodegib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERIVEDGE (DIN 02409267) under ATC L01XJ01 VISMODEGIB. Indications are not published in the Drug Product Database —… | DIN02409267 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |